Literature DB >> 29020002

First metabolic oncology inhibitor gets FDA green light, with record price tag.

Ken Garber.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29020002     DOI: 10.1038/nbt1017-895

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   68.164


× No keyword cloud information.
  3 in total

1.  Oncology's energetic pipeline.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2010-09       Impact factor: 54.908

2.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

3.  Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Authors:  Michael D Amatangelo; Lynn Quek; Alan Shih; Eytan M Stein; Mikhail Roshal; Muriel D David; Benoit Marteyn; Noushin Rahnamay Farnoud; Stephane de Botton; Olivier A Bernard; Bin Wu; Katharine E Yen; Martin S Tallman; Elli Papaemmanuil; Virginie Penard-Lacronique; Anjan Thakurta; Paresh Vyas; Ross L Levine
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

  3 in total
  1 in total

1.  Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China.

Authors:  Zhiqiang Wang; Zhibo Zhang; Yong Li; Li Sun; Dezhen Peng; Danyu Du; Xian Zhang; Luwei Han; Liwen Zhao; Ligong Lu; Hongzhi Du; Shengtao Yuan; Meixiao Zhan
Journal:  Acta Pharm Sin B       Date:  2021-03-09       Impact factor: 11.413

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.